Table 1 –
Demographics:
| Demographics | |
|---|---|
| Age, years, median (IQR) | 62.7 (57.0–68.0) |
| Gender, % male (n) | 46.3% (25) |
| BMI, kg/m2, median (IQR) | 25.6 (22.2–27.2) |
| Race % (n) | |
| Caucasian | 85.2% (46) |
| African American | 10.9% (5) |
| Other | 4.4% (2) |
| ASA Class, % (n) | |
| I | 0.0% (0) |
| II | 20.4% (11) |
| III | 72.2% (39) |
| IV | 1.9% (1) |
| Co-Morbidities, % (n) | |
| Hypertension | 48.2% (26) |
| Diabetes Mellitus | 16.7% (9) |
| Coronary Artery Disease | 7.4% (4) |
| Chronic Kidney Disease | 1.9% (1) |
| Smoking History, % (n) | |
| Current Smoking | 11.1% (6) |
| Past Smoking | 11.1% (6) |
| Current Moderate Alcohol Use, % (n) | 18.5% (10) |
| Preoperative Characteristics | |
| Presenting Symptoms, % (n) | |
| Weigh Loss | 42.6% (23) |
| Abdominal Pain | 77.8% (42) |
| Neoadjuvant Chemotherapy, % (n) | 98.2% (51) |
| FOLFIRINOX | 70.4% (38) |
| Gemcitabine/Abraxane | 20.4% (11) |
| Other | 7.4% (4) |
| Duration of Neoadjuvant Therapy, months, median (IQR) | 4.0 (4.0–6.0) |
| Neoadjuvant Radiotherapy, % (n) | 94.4% (51) |
| SBRT | 74.1% (40) |
| Standard RT | 20.3% (11) |
| Laboratory Values, median (IQR) | |
| CA 19–9 (U/ml) | 68.9 (34.1–359.9) |
| Bilirubin (mg/dL) | 0.4 (0.3–0.6) |
| Creatinine (mg/dL) | 0.8 (0.7–0.9) |
| Albumin (g/dL) | 4.2 (3.9–4.5) |